Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript

Celcuity has completed one Phase III of gedatolisib and expects a second Phase III readout soon in second-line breast cancer; a first-line breast cancer study and an early-phase prostate cancer study are also ongoing. The company’s platform isolates and quantifies live patient tumor cell activity to identify likely responders to targeted therapies; gedatolisib (pan-PI3K/mTOR inhibitor) was first developed beginning in 2021.

Analysis

Celcuity’s live-cell functional assay, if reproducibly predictive, changes the economics of targeted drug development more than it does diagnostics. A functional readout that meaningfully raises objective response rate (e.g., doubling response in a biomarker-positive cohort) shortens required sample sizes by ~40-60% for superiority trials, cutting trial spend and time-to-proof by quarters rather than years; that asymmetry makes Celcuity a convex acquisition target for mid-to-large pharma seeking de-risked assets. Conversely, failure to translate to clinical benefit carries binary downside — investors should treat upcoming clinical/regulatory inflection points as high gamma events with asymmetric payoff profiles.

Second-order operational frictions matter: functional assays that require viable tissue impose logistics costs (cold-chain, expedited pathology workflows) that will either force Celcuity to build a processing network or to partner with national lab operators, compressing eventual gross margins but accelerating scale. Payer adoption lags clinical validation; expect a 12–24 month runway between positive pivotal evidence and broad reimbursement, during which partnership or bridge financing becomes the key determinant of valuation realization. Regulatory signaling will disproportionately affect M&A appetite: an FDA acceptance/endorsement of a functional CDx paradigm would create a valuation step-change for companies owning that IP.

Competitive dynamics tilt toward consolidation. Traditional genomic-only players risk niche erosion in indications where phenotype predicts response better than genotype; incumbents may respond by acquiring or partnering with functional assay providers, increasing bid risk for Celcuity. For traders, the combination of high event risk, meaningful upside on positive readthroughs, and non-trivial operational capital needs favors event-driven, hedged exposure rather than unhedged long-only positions.

Key Decisions for Investors

• Long CELC via a defined-risk options spread: buy a 3–6 month CELC 25% OTM call and sell a 6–12 month 75% OTM call to cap cost. Rationale: captures near-term binary upside from clinical/partnering catalysts while limiting premium loss; target return 2–4x if positive readthrough, max loss = premium paid.
• Pair trade to isolate idiosyncratic signal: buy CELC stock (or calls) and short IBB or XBI equal dollar notional for 6–12 months. Rationale: neutralizes sector beta; wins if Celcuity-specific validation/partnering occurs. Risk: sector rally could still pressure small-cap biotech liquidity; set a 20% stop-loss on the gross long leg.
• Hedge existing directional exposure: if holding CELC equity, buy 9–12 month CELC puts at ~15–20% OTM to cap downside through the next regulatory/partnership window. Rationale: protects against binary negative outcome that could compress valuation to cash-runway multiples; cost acceptable relative to >50% potential drawdown risk in worst-case scenarios.